Immunotherapy in pediatric acute lymphoblastic leukemia
The 5-year survival rate for children and adolescents with acute lymphoblastic leukemia (ALL) has improved to more than 90% in high-income countries. However, further increases in the intensity of conventional chemotherapy would be associated with significant adverse effects; therefore,...read more
Mentioned in this Paper
BCR protein, human
Administration of Antineoplastic Agent
Monitoring - Action
References currently unavailable
We're still populating references for this paper, please check back later.
No citations available
This paper may not have been cited yet.